marijuana stocks news

General Cannabis, A Wave of Cannabis Legalization Initiatives on the Horizon

On August 10th, CANN shares were trading at $2.17 per share and on September 19th hit a recent high of $4.49 per share. Since then CANN shares had consolidated at about $3.20 per share.

General Cannabis Corp. is expanding its presence on the East Coast with the opening of a New York office. The New York office provides General Cannabis a strategic location to better serve existing East Coast clients while also attracting new talent and partnerships as the cannabis market in the eastern U.S. continues to develop. Further, the opening of the New York office provides a hub for current clients looking for East Coast expansion opportunities.

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Novus Acquisition and Development, Corp. (NDEV) to File as a Cannabis HMO in the State of California

Novus to File as a Cannabis HMO in the State of California…

$GRNH Introduces Sustainable Home Gardens

Greengro Technologies Introduces Sustainable Home Gardens From Subsidiary Vertical Hydrogarden Vertical Gro…

AbbVie Inc. (ABBV) Announces Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia

AbbVie Announces Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia under…

$GRNH Initiates the First Phase of Its Multi-Faceted Collaboration

Greengro Technologies Initiates the First Phase of Its Multi-Faceted Collaboration With Affiliate…